The researchers found disease-related signatures in the immune repertoire of affected patients as well as changes associated with treatment.
A pair of studies has established a potential role for specific gut bacteria in the progression of MS, suggesting therapeutic targeting of the microbiota as a potential treatment.
The researchers used this approach to show how non-coding variation associated with human immune dysfunction alters context-specific gene programs.
The newly announced Microbiome Immunity Project seeks to discover links between autoimmune diseases and bacteria in and on the human body.
TreeWAS provides a method for identifying gene variant-phenome associations in heterogenous biobank data without compromising phenotypic resolution.
With new gene sequencing panels, investigators made firm or possible diagnoses in almost one-third of undiagnosed autoinflammation and vasculitis cases.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology.
The firm's recent funding round will support its CLIA-certified laboratory that opened last year and the launch of its first RNA-based diagnostic test.
The algorithm identifies proteins in blood samples taken after bone marrow transplants that predict patients at risk for severe graft-versus-host disease.
The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
A genome-wide association study of more than 2,700 individuals with Crohn's disease uncovered prognosis-related loci distinct from those linked to disease risk.
The team identified gene expression patterns that can determine how severe a patient's systemic sclerosis is and if treatment has been effective.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The studies looked at applications including predicting disease progression, guiding drug tapering, and identifying patients at risk of related conditions.
The firm brought in total revenues of $177.5 million in the first quarter, compared to $183.5 million in Q1 2016, beating the consensus Wall Street estimate.
In colon tissue samples from individuals with Crohn's disease, researchers discovered either colon- or ileum-like expression features.
A University of Colorado School of Medicine-led team reported 23 new loci associated with vitiligo susceptibility.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.